The role of ACEI/ARBS in reducing morbidity in non- diabetic pts with an IHD with LVEF>= 50. At North state, Sudan. From October 2026 to January 2027.
القسم الأول: معلومات الباحث / Principal Investigator Information
القسم الثاني: تفاصيل الدراسة البحثية / Research Study Details
القسم الثالث: الجوانب الأخلاقية / Ethical Considerations
القسم الرابع: قائمة المرفقات المطلوبة / Required Attachments
القسم الخامس: الإقرار والتوقيع / Acknowledgment and Signature
معلومات الباحث / Researcher Information
DALAL NOURELDIN FADLELMULA MOHAMEDELAMIN
dalal.nooreldein@gmail.com
002410004033
مستشفى دنقلا التخصصي و مركز الجميح لامراض السكري
اسم المؤسسة التي سيتم فيها عمل البحث / Name of the institution where the research will be conducted
Dongola, north state
معلومات الدراسة / Study Information
أبحاث طبية / Medical Research
messages.degree_medical_research - messages.degree_medical_research
21,000.00 SDG
To study outcome regarding morbidity from using ACEI/ARBS in non-diabetic patient with IHD with LVEF>=50 and its associated factors. I will do total coverage for the selected population
Oct 25, 2026 - Feb 15, 2027
Oct 25, 2026 - Jan 31, 2027
الاعتبارات الأخلاقية / Ethical Considerations
Written
Limit variables to those required for the specific objectives. Avoid collecting names, national ID numbers, full addresses, phone numbers, or other direct identifiers unless ethically justified. Replace patient identifiers with a coded study ID on all questionnaires
No potential risks to the participants
By focusing specifically on the non-diabetic subgroup, the study isolates the effect of these drugs in a population where the indication is less clear